Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma
暂无分享,去创建一个
B. Redman | J. Sosman | J. Kirkwood | A. Ribas | L. Camacho | T. Gajewski | S. Antonia | D. Pavlov | C. Bulanhagui | J. G. Navarro